Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
"Actinium has amassed extensive clinical experience, technical know-how and research capabilities for the development of next-generation targeted radiotherapies that we are excited to bring to this collaboration with AVEO, which has a portfolio of high-affinity antibodies and is currently commercializing FOTIVDA (tivozanib) in advanced RCC. We believe ErbB3 is a validated and differentiated target that is aptly suited for radio-conjugate development. Using our AWE platform, we will harness the powerful Ac-225 payload to enhance targeted cell killing against a target that is overexpressed in a number of cancers that are difficult to treat with traditional oncology therapies. A member of the epidermal growth factor family of receptors, ErbB3 has been gaining increasing recognition as a validated targeted, we are committed to rapidly advance and evaluate this novel Ac-225 ErbB3 targeted radiotherapy together with AVEO," said
"While we focus on the commercialization of FOTIVDA in advanced RCC,, we are pleased to announce this collaboration with Actinium in an effort to leverage our high-affinity antibody program to expand our robust portfolio with a potential first-in-class targeted radiotherapy ," said
Actinium's AWE technology platform has created a Ac-225 CD38 targeting ARC using the blockbuster myeloma antibody daratumumab (Darzalex®), in collaboration with EpicentRx for targeted radiotherapy CD47-SIRPα immunotherapy combinations and in collaboration with Astellas Pharma, to create theranostics for solid tumors. Actinium employs a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development to R&D and collaborations.
AVEO's ErbB3 targeting antibodies are designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers and has demonstrated preclinical activity in multiple tumor models.
About AVEO Oncology
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in
This press release includes "forward-looking statements" of Actinium and AVEO within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties... All statements, other than statements of historical fact, contained in this press release are forward- looking statements. The words "anticipate," "believe," "design," "expect," "hope," "intend," "may," "plan," "potential," "could," "should," "would," "seek," "look forward," "advance," "goal," "strategy," or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, among others, statements about: the potential efficacy, safety, tolerability and clinical utility of AVEO's ErbB3 targeting agent with Actinium-225 to form a novel Ac-225 ErbB3 targeted radiotherapy; the potential outcomes from the collaboration to provide Actinium and/or AVEO with opportunities to pursue further development and regulatory strategies; Actinium's strategy, prospects, plans and objectives for Actinium-225 and for Actinium generally; and AVEO's strategy, prospects, plans and objectives for its ErbB3 targeting agent and for AVEO generally. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements due to a number of important factors, including including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's and/or AVEO's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's and AVEO's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-and-aveo-oncology-enter-research-collaboration-agreement-to-develop-first-in-class-actinium-225-erbb3-targeting-radiotherapy-for-solid-tumors-301487304.html